The answer to that is yes and no. It is intended that some trials will be run using a biomarker to recruit and others only looking at the correlation between FTO and a response as a secondary endpoint at the end of the trial.
The upcoming EMD AML Stratum 2 trial will not be recruiting on the basis of a biomarker other than being EMD AML positive.
Ann: Race executes Israel AML Phase 2 Trial Contract, page-58
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.62 |
Change
0.015(0.93%) |
Mkt cap ! $276.0M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.55 | $456.4K | 284.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2659 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |